Research shows that the active form of vitamin D reduced scar-forming signals in eye tissue cells from people with thyroid eye disease, according to a 2026 laboratory study in Experimental Eye Research. Gram Research analysis finds the effect depends on vitamin D receptors, which were lower in these cells. The findings come from cells grown in a dish, so human benefit is not yet proven.

Thyroid eye disease can cause the tissues behind the eyes to stiffen and scar, leading to double vision, eye pain, and bulging eyes. A laboratory study published in Experimental Eye Research in 2026 looked at whether vitamin D could slow this scarring. Gram Research analysis of this work finds that the active form of vitamin D reduced several scar-forming signals in cells taken from people with the condition. The cells also had fewer vitamin D receptors, the molecules that let the body respond to vitamin D, and vitamin D helped restore them. When researchers blocked these receptors, vitamin D’s protective effect disappeared, suggesting the receptors are essential. These results come from cells grown in a dish, not from people, so they cannot yet show whether vitamin D would help patients. Still, the study points to a possible new target for treating this condition.

Key Statistics

A 2026 laboratory study published in Experimental Eye Research found that vitamin D suppressed TGF-beta1-induced scarring markers in eye tissue cells from people with thyroid eye disease.

A 2026 laboratory study in Experimental Eye Research reported that vitamin D lost its anti-scarring effect when the vitamin D receptor was knocked down in thyroid eye disease cells, indicating the receptor is required for the benefit.

A 2026 laboratory study in Experimental Eye Research found that cells from people with thyroid eye disease had lower basal vitamin D receptor levels than cells from people without the condition.

The Quick Take

  • What they studied: Researchers asked whether vitamin D can calm the scarring process in eye tissue from people with thyroid eye disease, and whether a specific vitamin D receptor is needed for that effect.
  • Who participated: The study used tissue cells collected from people with thyroid eye disease and from people without the condition. The exact number of donors was not stated in the summary, and the work was done in a laboratory, not with live patients.
  • Key finding: The active form of vitamin D reduced several scar-forming signals triggered by a growth factor called TGF-beta1. Cells from people with the disease had lower levels of vitamin D receptors, and vitamin D helped bring those levels back up. When the receptor was switched off, vitamin D’s protective effect was lost.
  • What it means for you: This is early laboratory evidence, not proof that vitamin D helps thyroid eye disease. Do not change any treatment based on this study. Talk with your eye doctor or endocrinologist before taking vitamin D for this condition.

The Research Details

This was a laboratory study. Scientists collected fibroblasts, which are the cells that build connective tissue, from the tissue behind the eyes of people with thyroid eye disease and from people without the condition. They grew these cells in dishes and exposed them to TGF-beta1, a signaling protein known to push cells toward producing stiff scar-like material.

Some cells were also treated with the active form of vitamin D, called 1 alpha,25(OH)2D3. The team measured levels of scar-related proteins and genes, including collagen I, fibronectin, alpha-SMA, and CTGF. They also measured the vitamin D receptor and a set of chemical messengers called Smad2 and Smad3 that relay the growth factor’s instructions inside the cell.

To test whether the receptor was truly necessary, the researchers used a lentiviral shRNA knockdown. This is a tool that lowers how much of a specific protein a cell makes. When the receptor was reduced this way, vitamin D no longer produced its protective effects, which is a strong test of cause and effect at the cell level.

Growing cells in a dish lets researchers control every variable, so they can see exactly which signals and receptors are involved. Comparing diseased and healthy cells shows whether a problem is present in the disease itself. Switching off the receptor and checking whether the effect disappears is a direct way to test whether the receptor is needed, which is more convincing than simply observing an association.

The study used a controlled design with comparison groups and a genetic test to check the role of the receptor, which strengthens the internal logic of the findings. However, the summary does not state how many donor samples were used, so it is hard to judge how varied the results are across different people. Cell studies also cannot fully reflect how tissue behaves inside the body, and the paper does not report results from animals or patients. The journal is a peer-reviewed scientific publication, but a single lab study should be confirmed by other teams before drawing firm conclusions.

What the Results Show

The main result was that vitamin D reduced the scar-forming activity triggered by TGF-beta1 in cells from people with thyroid eye disease. When these cells were exposed to the growth factor, they made more of the proteins that build stiff, fibrous tissue. Adding vitamin D lowered the levels of these markers, including collagen I and fibronectin, which are key building blocks of scar tissue.

The researchers also found that cells from people with thyroid eye disease started with lower levels of the vitamin D receptor than cells from healthy people. This matters because the receptor is how the cell detects and responds to vitamin D. The growth factor itself further suppressed the receptor, but vitamin D was able to restore its levels.

The team then showed that the receptor was essential. When they lowered the receptor’s levels in the cells, vitamin D no longer reduced scarring. This suggests that vitamin D’s effects depend on the receptor rather than on some other unrelated pathway.

Finally, vitamin D reduced the activation of Smad2 and Smad3, messengers that carry the growth factor’s scarring signal from the outside of the cell to its nucleus. This effect also disappeared when the receptor was knocked down, pointing to the receptor as a regulator of this signaling chain.

The researchers described the receptor and Smad signaling changes as a possible pathway linking vitamin D to scar control. Showing that a single pathway is involved gives scientists a specific molecular target to study further, which can be more useful than a general observation that vitamin D is beneficial. The findings also suggest that the receptor may be a biomarker, meaning a measurable sign, of how the disease tissue is responding, though this idea would need testing in patient samples.

Vitamin D is already known to have anti-inflammatory and anti-scarring effects in several tissues through the vitamin D receptor. This study extends that knowledge to the tissue behind the eyes in thyroid eye disease, an area where much less is known. It also fits with growing interest in the TGF-beta1 signaling pathway as a driver of fibrosis across many diseases, including conditions affecting the lungs, kidneys, and skin.

The study was done on cells grown in a laboratory, which cannot capture the full complexity of living eye tissue, immune responses, hormones, or the effects of treatments people already receive. The summary does not report how many donors were studied, which limits how confidently the results can be applied to all patients. The vitamin D used was the active laboratory form, which is not the same as the over-the-counter supplements people typically take, and the study did not test safe or effective doses in people. No animal or human trials are described, so it is not yet known whether these cell-level effects would translate into real improvements in eye symptoms or appearance.

The Bottom Line

Confidence is low to moderate that vitamin D plays a helpful role in thyroid eye disease, based on one laboratory study. The findings justify further research, including animal studies and carefully designed clinical trials. People with thyroid eye disease should not start high-dose vitamin D on their own based on this work. Current treatment decisions should remain with a qualified eye or thyroid specialist.

Eye specialists, endocrinologists, and researchers studying scarring diseases should pay close attention, since the study points to a possible new target. People living with thyroid eye disease may find it interesting, but they should discuss any supplement plans with their doctor. People without thyroid eye disease do not need to change anything based on these findings.

Laboratory findings like these usually take years to move into animal testing and then into human trials. Based on typical research timelines, any treatment built on this idea would likely need several years of testing before it could be considered for patients, and the outcome is uncertain.

Frequently Asked Questions

Can vitamin D help with thyroid eye disease?

Laboratory research published in 2026 suggests vitamin D may reduce scar-forming activity in eye tissue cells from people with thyroid eye disease. The work was done on cells in a dish, not in patients, so it does not prove that vitamin D treats the condition. Talk with your eye doctor before making any changes.

What does vitamin D do to scarring in the eye tissue?

In a 2026 cell study, active vitamin D lowered levels of collagen I and fibronectin, proteins that build stiff scar tissue, after cells were exposed to the growth factor TGF-beta1. It worked by restoring vitamin D receptors and calming Smad2 and Smad3 signaling inside the cells.

Why do people with thyroid eye disease have more scarring?

Thyroid eye disease causes tissue behind the eyes to produce excess scar-like material, which can stiffen eye muscles and cause double vision or bulging. A 2026 study found that cells from people with the condition also had lower levels of vitamin D receptors than healthy cells, which may contribute to this process.

Should I take vitamin D supplements for thyroid eye disease?

The 2026 study used a lab form of active vitamin D on cells and did not test supplements in people or identify a safe dose. Do not start high-dose vitamin D on your own. Ask your eye specialist or endocrinologist whether testing your vitamin D level and taking a supplement makes sense for you.

Want to Apply This Research?

  • If you have thyroid eye disease and your doctor approves vitamin D monitoring, track your blood vitamin D level through regular lab tests and log the results alongside any changes in eye symptoms, such as double vision episodes, eyelid swelling, or eye pain, rated on a simple 0 to 10 scale once a week.
  • Use the app to log daily vitamin D intake only if your doctor has recommended a specific amount. Set a reminder to bring your symptom log and supplement list to each medical appointment so your care team can review what is working.
  • Review your symptom log and any blood test results with your care team every three to six months. Look for patterns over time, such as whether symptoms change when supplement doses or other treatments change, and share these trends with your doctor rather than drawing conclusions on your own.

This article summarizes a laboratory study performed on cells, not on people, and its findings are preliminary. It is not medical advice and should not be used to start, stop, or change any treatment, including vitamin D supplements. Anyone with thyroid eye disease or eye symptoms should consult a qualified eye care professional or endocrinologist.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Vitamin D3 Attenuates TGF-β1-Induced Fibrosis via VDR Signaling in Thyroid Eye Disease Orbital Fibroblasts. , Experimental eye research (2026). PubMed 43057444 | DOI
Topics
vitamin D thyroid eye disease orbital fibroblasts fibrosis vitamin D receptor TGF-beta1 Smad2/3 signaling eye scarring